EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don Dorsey who wrote (1908)	4/16/1999 2:16:00 AM
From: marc ultra	Read Replies (1) of 2135

Even though you didn't ask for it I'll give you a long's point of view. Mouse endostatin had a remarkable anti-tumor effect on human tumors put on mice and a combination of endostatin and angiostatin was even more remarkable virtually curing the cancer. The NCI replicated the endostatin results after some technical problems. Before the replication the WSJ did a reverse hype and did an absurd trashing of the drugs and even Judah Folkman who most cancer researchers would agree will get a Nobel Prize for his work in tumor angiogenesis. The drugs are species specific and human endostatin as well as angiostatin have been shown to have anti-tumor activity in mice and should be even much more powerful in humans. Using a yeast expression vector recombinant human endostatin has been made in quantity by ENMD and its highly respected contract manufacturer Covance and Phase I trials have been scheduled to start at two cancer centers under NCI auspices probably in the fall as soon as protocols are written up and any further tests are done on the drug to be used. ENMD's human endostatin is soluble and appears to be stable and should be able to be given by IV infusion without problem. All of these patients will have advanced cancer so even tough phase I studies will be testing safety all the patients will be monitored carefully for tumor response as well as any side effects. As to Angiostatin ENMD is also able to produce it in the same yeast system and testing should begin at the end of the year. BMS was trying to produce angiostatin by another method which led to their difficulty in getting consistent product and their decision to drop it particularly as the individual who was most responsible and enthusiastic about it had left the company. In addition to this ENMD makes money off of all the thalidomide CELG is selling and has other products. If you look at these facts and realize that if the testing of endostatin several months down the road shows significant efficacy that this drug will run through trials and get approval in record time This story is real and compelling and one negative article from the WSJ in the past that has already proven incorrect since and then someone on SI who put out an absurd press release which misunderstood obvious facts to the contrary, this has the potential to be one of the greatest medical and investing stories in history. Obviously a failure in humans that can't be fixed or an unexpected severe side effect that can't be corrected could turn this into a failure Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next